Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna R. Carta, Augusta Pisanu, Ezio Carboni
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.4061/2011/689181
Tags: Add Tag
No Tags, Be the first to tag this record!